fragma1
28 Feb 2018
Re: Calculus capital Video Forgot to put the link to the interview [link]
fragma1
28 Feb 2018
Calculus capital Video Today's Publication of Calulus capital Scancell interview summary, courtesy of rosesI thought I might condense the key points from the interview for those that have not watched it.- "A strong patent real estate which gives potential to be a game changer in the immunotherapy arena "- "the net result of the trials is the effective killing of cancer cells"- "Immunotherapies are on the market but Scancell is looking to replace them with much higher survival rates and improved safety profiles"- Focus is on hard to treat cancers with significant opportunities for cancers that are unresponsive to current therapies.- CRUK will be funding SCIB 2 trail and SCLP will have the option to buy the data for " A nominal fee" or enter a revenue sharing agreement.- Genetech "looking to to take up a commercial licence once completed"- " Key opinion leaders are running our trials "-" Moditope patent is 'basically granted' and covers the use of ANY CITRINULATED PEPTIDE for the treatment of cancer, underpinning that we were the first group to realise the potential in cancer"- "What we have shown is that our combination of peptides gave us 100% survival in a very aggressive tumour model, In other words, it rejected every single tumour in every single animal - I have never in 30 years seen anything that potent with any of these vaccines"- Modi patent covers all citrulinated proteins. 37 discovered so far, maybe more on the way- LD talks as if the £20 million CRUK money is already a done deal- 21 of the best scientists in Europe are working on CRUK modi 3-"Professor Taheem head of BionTech is extremely interested in MODI and really intrigued by the whole concept"- "Important to recognise that CRUK is a research charity, not just a charity. This is very much a validation of Scancell's work. These are scientists who are only taking on programs that show promise and you only get your foot in the door if they think you have something very interesting and it's valid "
II Editor
20 Feb 2018
NEW ARTICLE: A small-cap planning a breakout move "Scancell Holdings (LSE:SCLP) For the n'th year running, the USA managed to surprise by sneaking in "Washington's Birthday" as an excuse to close the markets. Quite why a president who promoted a gun culture which led to today's USA is feted ..."[link]
II Editor
19 Feb 2018
NEW ARTICLE: Trends and Targets for 20/02/2018 " SCANCELL HOLDINGS (LSE:SCLP) For the n'th year running, the USA managed to surprise by sneaking in "Washington Birthday" as an excuse to close the markets. Quite why a President who promoted a gun culture which led to todays USA is feted ..."[link]
II Editor
11 Feb 2018
NEW ARTICLE: Trends and Targets for 12/02/2018 " FTSE THIS WEEK (FTSE:UKX) We should find a way of building our articles which gives folks an idea of which bit to read. Due to our habit of giving "if x then y" and "if a then b" scenario, it would be useful if we could always position each ..."[link]
fragma1
11 Feb 2018
Scancell in the Daily Mail today a [link]
fragma1
11 Feb 2018
Scancell on BBC news - todays papers [link] the daily mail
II Editor
07 Dec 2017
NEW ARTICLE: Trends and Targets for 8/12/2017 " FTSE FOR FRIDAY (FTSE:UKX) Sometimes, the utter boredom inflicted by the market leads one down a strange path. Thursday was a case in point, the morning session used productively by figuring out the lead guitar bit of Girls Aloud tune, "Love ..."[link]
Michaelhighbar
23 Aug 2017
Some good publicity Scancell was in last weekend's FT alongside two other AIM companies:[link] could explain the recent rise and perhaps it is also linked to the anticipation of the upcoming FDA admission with respect to phase two trial:[link] study will be in the StatesInvestors have known for a while that the next SCIB1 study will be in the United States, something Scancell reiterated today.A new batch of the drug has been manufactured and will be released for clinical use later this quarter.That will coincide with the submission of the investigational new drug (IND) application to the US Food and Drug Administration for a phase II trial, which is on track to be submitted before the end of September.“Our next study, which will be in the US, will assess the potential for an increase in response rate in patients with malignant melanoma when treated with SCIB1 and a checkpoint inhibitor,” said Goodfellow.Don’t forget, Richard Goodfellow is presenting at the next Proactive Investors One2One Forum on Thursday (13 July) in London. Click here for more details."
Ripley94
13 May 2017
Re: Acceleratred book buid placing RNS Just looked at LSE site posts on there within two mins of RNS... 12.09 / 12.11 .. with linksMust check over there in future.
Ripley94
13 May 2017
Re: Acceleratred book buid placing RNS Odd .. i looked at news on this site yesterday before posting . The second RNS with placing results was not there @ 9am when i posted.My guess of 10p was spot on it now appears.I now can see 2nd RNS of results later in the day Thursday 11th may.No matching OO to us holders this year at same price as this placing ?
Ripley94
12 May 2017
Re: Acceleratred book buid placing RNS Can not see brokers flogging these to punters above 10 with the price today @ 11
Ripley94
11 May 2017
Acceleratred book buid placing RNS But no clue to price anyone had a phone call ?Down to 10p.... -9% .. only clue....
Ripley94
28 Apr 2017
Re: Fund raising result Yesterday might of been bottom this was a Nigel Somerville ( SP ) tip 19 June 2016.Seems his boss wasn't to keen on it and has been proved a better picker with this one.EIS tax reliefs made this attractive for many.
Ripley94
27 Apr 2017
Re: Fund raising result Not looking good 11 months after OO. big drop of 11% today now 11.5pTalk of another fund raise. Maybe that will be a placing this time ?
